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Abstract
Migraine  is  a  common  disabling  neurovascular  primary  headache  disorder.  The
pathomechanism is not clear, but extensive preclinical and clinical studies are ongoing. The
structural basis of the leading hypothesis is the trigeminovascular system, which includes the
trigeminal ganglion, the meningeal vasculature, and the distinct nuclei of the brainstem, the
thalamus and the somatosensory cortex. 
This review covers the effects of sensory (calcitonin gene-related peptide, pituitary adenylate
cyclase-activating  polypeptide  and  substance  P),  sympathetic  (neuropeptide  Y)  and
parasympathetic  (vasoactive  intestinal  peptide)  migraine-related  neuropeptides  and  the
functions of somatostatin, nociceptin and the orexins in the trigeminovascular system. These
neuropeptides may take part in neurogenic inflammation (plasma protein extravasation and
vasodilatation) of the intracranial vasculature and peripheral and central sensitization of the
trigeminal system. 
The results  of human clinical  studies are discussed with regard to the alterations in these
neuropeptides  in  the  plasma,  saliva  and  cerebrospinal  fluid  during  or  between  migraine
attacks, and the therapeutic possibilities involving migraine-related neuropeptides in the acute
and prophylactic treatment of migraine headeache are surveyed. 
Keywords:  migraine,  neuropeptides,  neurogenic  inflammation,  peripheral  and  central
sensitization, trigeminovascular system 

Highlights
 Although  migraine  is  a  highly  prevalent  neurovascular  disease,  its  exact
pathomechanism has not yet been elucidated.
 The  leading  hypothesis  is  based  on  neuropeptide-related  modulation  of  the
trigeminovascular system. 
 The role played by the neuropeptides in migraine is an active area of preclinical and
clinical research.
 Neuropeptides  and  their  receptors  might  well  play  a  part  in  the  future  acute  and
prophylactic therapy of migraine. 
Introduction 
Migraine is a highly prevalent devastating primary headache disorder that affects around 16%
of the adult population, with a female to male ratio of 3:1 . The 1-year prevalence of migraine
has been reported to be 10-12% . It is ranked among the top 10 causes of disability worldwide
. The two main subtypes of this primary headache syndrome are migraine with and migraine
without aura. This pain syndrome is typically characterized by recurrent attacks of unilateral,
pulsating headache of moderate or severe intensity, which is aggravated by physical exercise .
Migraine-associated symptoms include nausea and/or vomiting, photophobia or phonophobia
and  allodynia.  The  aura  phenomenon  usually  precedes  the  headache;  this  phase  is
characterized by the development of transient focal neurological symptoms, the most common
being  a  visual  disturbance  .  In  spite  of  intensive  scientific  research  activities,  the  exact
pathomechanism of migraine remains unknown. Controversies persist concerning the origin
of the migraine headache, e.g. vascular or neuronal, cortical or brainstem . Among the several
hypotheses relating to migraine,  the leading ones are connected with the activation of the
trigeminovascular  system  (TS),  the  cortical  hyperexcitability  and  the  neuronal  and  glial
interactions . 
In  this  review,  we focus  on  the  pivotal  role  of  the  neuropeptides  calcitonin  gene-related
peptide  (CGRP), vasoactive  intestinal  peptide  (VIP),  pituitary adenylate-cyclase  activating
polypeptide  (PACAP),  neuropeptide  Y  (NPY),  substance  P  (SP),  somatostatin  (SST),
nociceptin (NOP) and the orexins (OXs) in the modulation of the TS and the other migraine-
related nervous system structures. The alterations in these peptides during migraine attacks or
headache-free periods are surveyed, together with the presumed roles of these neuropeptides
and their receptors in the acute and prophylactic therapy of migraine.  
CGRP
CGRP  is  a  37-amino  acid  neuropeptide  derived  from  the  gene  encoding  calcitonin  on
chromosome 11  (Table 1).
The basic function of CGRP in the pathomechanism of migraine was proposed more than two
decades ago . Human CGRP has two isoforms: α-CGRP and β-CGRP . α-CGRP is widely
distributed in the central (CNS) and peripheral nervous systems (PNS) . Most of the cranial
vasculature is innervated by α-CGRP-containing C and Aδ sensory nerve fibres . β-CGRP,
which differs from α-CGRP by 3 amino acids, is located in the enteric nerve terminals . 
The  TS  includes  the  pseudounipolar  neurones  of  the  trigeminal  ganglia  (TRIG).  The
peripheral  branch  of  these  first-order  neurones  innervates  the  intracranial  meningeal
vasculature, while the central nerve endings project to the nociceptive second-order neurones
in the trigeminal nucleus caudalis (TNC). The migraine pain-related secondary nociceptive
neurones receive convergent synaptic input from the spinal cervical 2 (C2) dorsal root ganglia
(DRG) and from the meningeal innervated part of the TRIG. From the second-order neurones,
the  information  is  conveyed  to  the  third-order  neurones  in  the  thalamus  and then  to  the
sensory cortex . 
In  the  mid-1990s,  the  Weiller  group  made  use  of  high-resolution  positron  emission
tomography in their elegant demonstration that the blood flow of specific brainstem nuclei,
called "migraine generators" (the locus coeruleus - LC, the periaqueductal grey matter – PAG,
and the raphe nuclei), and the cerebellum was increased during spontaneous migraine attacks .
CGRP is widely expressed in the migraine-related structures such as the TRIG, the TNC and
the upper part of the cervical spinal cord and the human LC . A high density of expression of
CGRP-receptor  components,  e.g.  the  calcitonin  receptor-like  receptor  (CLR) and receptor
activity-modifying  protein  (RAMP)-1,  is  found  in  the  nerve  fibres  in  the  TNC .  Recent
observations suggest the role of the cerebellum and the CGRP in the modulation of the pain . 
In  the  TRIG,  CGRP  is  co-expressed  with  SP,  5-hydroxytryptamine  (5-HT),  nitric  oxide
synthase and PACAP .  The satellite  glia  cells  (SGCs) of the TRIG express the CLR and
RAMP-1 . Recent data point to the pivotal role of the neuronal-glia interaction in the TRIG .
The release of CGRP during the neuronal activation of the TRIG stimulates the SGCs, which
release proinflammatory cytokines, thereby further modulating the neuronal response . This
observation  permits  a  new approach to  an understanding of  the intraganglionic  signalling
process. 
The CGRP-immunoreactive  (-ir)  peripheral  branch of the neuronal  elements  of the TRIG
supplies mainly the pial arterioles of the cortical surface and the vasculature of the intracranial
dura mater . CGRP is a very potent endogenous vasodilatory neuropeptide in the cerebral
vasculature  .  During  activation  of  the  TS,  CGRP  gives  rise  to  neurogenic  inflammation
(vasodilatation and plasma protein extravasation) in the meningeal vasculature and to mast
cell degranulation, this process leading to peripheral sensitization . The clinical manifestation
of this peripheral sensitization is the throbbing nature of the migraine headache, while routine
physical  activity worsens the headache during migraine attacks  .  In the brainstem, CGRP
causes central sensitization of the second-order neurones in the TNC and in the third-order
neurones  in  the  thalamus   (Figure  1.).  This  process  leads  to  cephalic  and  extracephalic
allodynia clinically .
An immunohistochemical study revealed CGRP-ir fibres in the vicinity of the neurones of the
sphenopalatine ganglia (SPG), and CLR and RAMP-1 immunoreactivity in the SGCs . It is
presumed that  the sensory system influences  the parasympathetic  cranial  ganglia,  e.g.  the
SPG, during the activation of the TS . 
CGRP could act as a biomarker of migraine . Elevated levels of CGRP in the serum in the
cranial outflow at the external jugular and cubital vein, and in the saliva, have been detected
during  spontaneous  migraine  attacks,  and enhanced CGRP plasma levels  are  observed in
nitroglycerine  (NTG)-induced  migraine  attacks  .  Increased  CGRP  levels  have  also  been
measured in the peripheral blood in the cubital vein outside migraine attacks . One research
group did not confirm an elevated CGRP level in the external jugular venous blood during
migraine without aura attacks . Another research group reported a significant decrease in the
CGRP level in the cubital venous plasma during migraine attacks without aura as compared
with the level outside the attack period . The differences observed between CGRP levels in
plasma obtained from the external jugular and the cubital vein might be explained by the short
half-life of the peptide, e.g. a fast degradation within the plasma . The baseline level of CGRP
in the saliva has been found to be significantly elevated between attacks in migraine subjects
as compared with controls . A clinical study revealed that an increased level of CGRP in the
saliva was predictive of responsiveness to a 5-HT 1B/1D receptor agonist, rizatriptan . In female
migraineurs during NTG-induced migraine attacks the plasma CGRP concentration proved to
be  decreased  in  parallel  with  the  headache  intensity  score  after  the  administration  of
sumatriptan . An increased CGRP level has been reported in the cerebral spinal fluid (CSF) in
chronic migraine subjects as compared with control subjects . Intravenous administration of
CGRP caused migraine-like attacks both in migraineurs with aura and in those without aura .
In contrast, CGRP infusion did not cause migraine attacks in a rare subgroup of migraineurs,
familial hemiplegic migraineurs . 
Overall, CGRP may play a crucial role in the neurogenic inflammation and in the peripheral
and central sensitization of the TS as concerns the pathomechanism of migraine, and it could
be a possible biomarker of migraine headache. 
VIP
VIP, first isolated from the ovine intestine, and consists of 28 amino acids . It belongs in the
secretin/glucagon/VIP  superfamily  of  neuropeptides.  It  acts  through  the  family  of  seven
transmembrane  G  protein-coupled  receptors,  e.g.  vasoactive  intestinal  polypeptide  the
receptors 1 and 2 (VPAC1 and VPAC2) . VIP is a marker of the parasympathetic nervous
system and exerts a strong vasoactive capability influence on the cranio-cervical vasculature .
In the early 1990s, a clinical study revealed that the level of VIP in the plasma was elevated
during  spontaneous  migraine  attacks  in  patients  who  demonstrated  symptoms  of
parasympathetic activation . Peripheral stimulation of the peripheral branch of the neuronal
elements of the TRIG (superior sagittal sinus) in the cat revealed a markedly increased level
of VIP in external jugular vein blood samples . Immunohistochemical studies later revealed
VIP-ir nerve fibres in the "migraine generators", e.g. the nucleus raphe magnus (NRM) and
PAG . VIP-ir nerve fibres were not seen in the TNC or at the C1 and C2 levels of the spinal
cord . 
A recent clinical study demonstrated that increased VIP levels were detected in chronic and
episodic migraine patients in the attack-free period versus controls . In another study, the VIP
levels in the peripheral blood interictally in chronic migraineurs were found to be higher those
in control subjects . Administration of onabotulinumtoxin type A is efficacious as treatment
for  chronic  migraine  .  VIP  acts  as  a  potential  predictor  of  onabotulinumtoxin  type  A
responders versus non-responders . During spontaneous migraine attacks, the VIP level was
significantly reduced in the external jugular venous blood after rizatriptan administration . In
the  saliva,  the  VIP  level  was  significantly  elevated  interictally  in  migraine subjects  as
compared with controls, and following sumatriptan treatment the VIP level was significantly
decreased during the migraine attack . 
These VIP data suggest that the parasympathetic system may play a role in the initiation of
the migraine attack. This statement is supported clinically by the finding that roughly 30% of
migraine patients develop cranial autonomic parasympathetic symptoms such as lacrimation,
rhinorrhoea and eyelid oedema . Immunohistological findings have revealed CGRP-ir nerve
fibres in the SPG, CLR immunoreactivity in the SGCs and RAMP-1 immunoreactivity in the
neurones and SGCs in the SPG . These data suggest an interaction between the sensory and
parasympathetic systems in the cranial ganglia . 
VIP exerts a strong vasodilatatory effect on the craniocervical vasculature . One clinical study
revealed that a VIP infusion causes strong dilatation of the superficial temporal artery, but
none of the patients reported migraine attacks . It was recently reported that a VIP infusion
induced  marked  dilatation  of  the  extracranial,  but  not  the  intracranial  arteries  in  female
migraineurs without aura, and only 18% of the migraine patients experienced migraine-like
attacks . 
Overall,  therefore,  VIP is a strong vasodilator with a low capability to induce a migraine
attack. 
PACAP
PACAP,  a  potent  stimulator  of  adenylate  cyclase  and  a  biologically  active,  important
neuropeptide, was first isolated from the ovine hypothalamus more than 25 years ago . The
gene of PACAP is localized on chromosome 18 . There is a more dominant 38 amino acid-
containing form, PACAP-38, and a C-truncated form, PACAP-27 . These peptides exhibit
structural and functional similarities to VIP . Both forms can bind to G-protein-coupled VIP
(VPAC1 and  VPAC2)  and  specific  PACAP  (PAC1)  receptors  .  PACAP-38  is  widely
distributed  in  many organs and is  therefore implicated  in  various  biological  functions.  In
human and animal tissues, PACAP and its receptors have been detected in the sensory TRIG
and the parasympathetic SPGs and otic ganglia . Moreover, they are closely related to the
vascular smooth muscles  and are present at  different levels of the CNS and PNS . High
concentrations of PACAP-38 have been detected among others in the human TNC  and the
LC , with moderate PACAP expression in the PAG , the raphe nuclei , the thalamus  and the
spinal  trigeminal  nucleus  .  PACAP binding  sites  have  been  identified  in  the  cortex,  the
thalamus,  the  hypothalamus,  the  brainstem ,  the  TRIG  ,  human  mast  cells  ,  the  middle
cerebral arteries (MCAs)  and the middle meningeal arteries (MMAs) . 
PACAP exerts various peripheral effects  and it has a pro-nociceptive role in the CNS . It has
functions  in  neuroinflammation   and  sensitization  .  Three  synergistic  theories  (vascular,
neuronal and mast cells) have been postulated to underlie the possible effects of PACAP in
the mechanisms of migraine. The role of PACAP has been investigated in the NTG-induced
animal model of the activated TS. NTG evoked marked migraine-like changes in wild-type
mice, but not in PACAP-deficient mice. The systemic administration of PACAP-38 elicited
the  symptoms  of  photophobia,  elevated  the  meningeal  blood  flow  and  exerted  neural
activation in the TRIG and TNC in wild-type mice,  whereas the corresponding alterations
were significantly less pronounced in the lack of  the PACAP gene . In another experiment,
the administration of NTG generated increases in the levels of PACAP-27 and PACAP-38
immunoreactivity in the TNC in the rat. Similarly, significantly elevated peptide levels were
observed in the TNC and also in the extracranial blood flow 90 and 180 min after electrical
stimulation of the TRIG in the rat, another model of activated TS . These data suggest that
PACAP may elicit peripheral and central sensitization and evoke meningeal vasodilatation.
An investigation of the direct vascular effects of PACAP-38 led to the finding that stimulation
of the superior sagittal sinus in the cat causes the extracranial release of PACAP . Moreover, a
magnetic  resonance imaging (MRI) angiographic study revealed that,  in  contrast  with the
MCAs PACAP-38-induced headache is associated with significant dilatation of the MMAs,
an effect which can be attenuated by the application of sumatriptan . The importance of the
PAC1 receptor has been emphasized , but there are results that intradermally injected PACAP-
38  or  VIP  can  elicit  mild,  short-lasting  cutaneous  pain  in  healthy  volunteers,  this  being
mediated primarily by the VPAC receptors . It has additionally been observed that PACAP or
VIP has lower potency and efficacy in the meningeal vessels than in the coronary arteries,
leading to the conclusion that the PACAP-induced migraine-like headache might not involve
meningeal vasodilatation . Although, the vascular action of PACAP-38 can not be excluded, it
appears  likely  to  be  a  slight  and  indirect  vasodilator  effect  .  It  has  been  demonstrated
clinically  that  the intravenous administration of PACAP-38 induces  delayed migraine-like
attacks and vascular alterations in patients with migraine without aura , whereas merely a
simple headache occurs in healthy volunteers. A more recent 24-h follow-up study revealed
that the infusion of PACAP-38 rather than VIP generates pronounced migraine-like attacks
and sustained vasodilatation of the extracranial arteries in migraineurs . Although  elevated
plasma PACAP-38 concentrations were recorded before the onset of the attacks, changes were
not observed in the levels of VIP and tryptase in the blood after the PACAP-38 infusion,
which  suggests  the  role  of  the  PAC1 receptors  . In  another  human  study,  significantly
increased PACAP-38 levels were detected in the ictal  phase of migraineurs relative to the
attack-free period, while significantly lower plasma peptide concentrations were measured in
the interictal period of migraineurs as compared with the healthy control group (Figure 2.). A
slight negative correlation has been demonstarted between the interictal plasma PACAP-38
level and the disease duration, suggesting that PACAP has vascular effects related to migraine
and it  can sensitize the trigeminal  sensory fibres directly ,  but the mast  cells  also have a
considerable role in these processes  (Figure 3.). It seems that PACAP-38-induced MMA
dilatation is probably caused by indirect, phopholipase C-mediated mast cell degranulation,
which might be implicated in the mechanisms of migraine . 
The experimental and clinical evidence lends support to the mediator role  of PACAP in the
initiation and/or promotion of migraine attacks . Recognition of the receptorial and signalling
mechanisms of PACAP might open up new perspectives for the development of non-peptide,
receptor-specific drugs. 
NPY
NPY, a 36-amino acid peptide, is a marker of the sympathetic nerve endings with long-lasting
vasoconstrictor  properties,  and  therefore  has  a  crucial  role  in  the  control  of  the  cerebral
circulation . In relationship with the craniocervical blood vessels, the sympathetic innervation
is supplied by the superior and inferior cervical  ganglia and the stellate  ganglion .  In the
sympathetic  nerve  terminals,  NPY  is  co-stored  and  co-released  with  norepinephrine  .
Immunohistochemical investigations have revealed that one of the distinct brainstem nuclei in
humans, the LC, as a "migraine generator", contains the C-terminal flanking peptide of NPY
immunoreactivity  in  the  neurones,  illustrating  their  adrenergic  nature;  the  LC  sends
noradrenergic-containing nerve fibres to the TNC, indicating that the TNC is influenced by
the adrenergic LC . 
NPY-ir nerve fibres densely innervate the cerebral dura mater, pial blood vessels and cerebral
arteries . 
In  young  migraineurs  with  aura,  the  plasma  NPY  level  is  increased  during  attacks,  but
reduced  in  the  interictal  period,  suggesting  the  role  of  NPY  in  the  pathomechanism  of
migraine with aura . 
After lumbar puncture, the NPY immunoreactivity in the CSF was reported to be higher in
migraineurs during the attacks as compared with controls , whereas another research group
did not observe a NPY immunoreactivity elevation in the suboccipital CSF or plasma during
attacks and attack-free periods of patients with migraine without aura . In migraine patients
with or without aura, the NPY immunoreactivity in the external jugular venous blood did not
alter during migraine attacks . 
In  summary,  NPY is  a  good  marker  of  the  intracranial  sympathetic  innervation,  but  the
evidence relating to its potent role in the pathomechanism of migraine pain is not pronounced.
SP
SP,  a  member  of  the  tachykinin  neuropeptide  family,  consists  of  11  amino  acids  .  Its
endogenous  receptor  is  the  neurokinin  1  (NK1)  receptor  .  SP is  widely expressed  in  the
trigeminal  sensory  nerve  fibres  .  Dense  SP-ir  nerve  fibres  have  been  observed  in  the
"migraine generators", e.g. the NRM, the LC and the PAG . In the TNC and in the dorsal
horns at the spinal C2 level, numerous SP-ir nerve fibres have been detected . SP has a potent
function  in  pain  transmission  in  the  different  regions  of  the  PNS and the  CNS .  During
activation  of  the  TS,  SP  induces  plasma  protein  extravasation  and  vasodilatation  in  the
cerebral dura mater ; this is blocked by the selective NK1 receptor antagonists . In the TNC,
SP performs nociceptive conduction . The NK1 receptor antagonists also have the ability to
inhibit the activation of the second-order neurones in the TNC after electrical stimulation of
the TRIG . Preclinical studies have revealed that stimulation of the peripheral branch of the
TRIG, e.g. electrical stimulation of the superior sagittal sinus, results in elevations of CGRP
and VIP, but not NPY and SP . No elevation of SP in the cranial venous outflow was detected
during  spontaneous  migraine  attacks  ,  whereas  the  salivary  SP  immunoreactivity  was
increased  during  spontaneous  migraine  attacks  without  aura  versus  the  level  in  control
subjects . In chronic migraine patients, the plasma and saliva levels of SP were higher than
those in control subjects, and associated with pain intensity . The plasma SP concentration
was observed to be enhanced in episodic migraineurs during the headache-free periods . In a
further study, the SP level in the platelets was higher in migraineurs than in the controls . 
Overall, SP has a strong plasma protein extravasation effect, but to date the role of SP in the
pathomechanism of migraine has not been fully confirmed. 
SST
SST (previously termed the somatotropin release-inhibiting factor) plays a pivotal role in the
regulation of the neuroendocrine system, as an inhibitor of the secretion of growth hormone,
thyrotropin-releasing hormone, insulin, glucagon, cholecystokinin, secretin, gastrin, motilin,
calcitonin and parathyroid hormone . Its precursor molecule, prepro-SST (116 amino acids),
undergoes cleavage to furnish two forms, SST-14 (14 amino acids) and SST-28 (28 amino
acids) . The SST-containing neurones are widely distributed in the CNS, e.g. in the cerebral
cortex,  hippocampus, hypothalamus, brainstem and spinal cord . SST acts on six different
SST receptor subtypes belonging in the G-protein-coupled receptor family . 
A  preclinical  animal  study  has  revealed  that  blockade  of  the  SST  receptors  by  the
administration  of  cyclo-SST to  the  posterior  hypothalamic  area  of  the  rat  resulted  in  an
antinociceptive effect on the dural electrical and facial thermal inputs in the TNC . In an early
clinical study, the SST immunoreactivity in the suboccipital CSF was decreased in migraine
patients  without  aura  during  the  attack-free  periods,  subsequently  further  decreasing  and
reaching statistically significant difference as compared with mixed neuropsychiatric group of
patients . CSF obtained by lumbar puncture exhibited a lower SST immunoreactivity level in
chronic migraine patients than in controls . In a double-blind parallel group trial, the treatment
of  migraine  attacks  with  the  subcutaneous  administration  of  a  long-acting  SST analogue
(octreotide, SMS 201-995) resulted in a significant reduction of headache pain . In a clinical
study  involving  migraine  patients  with  or  without  aura,  withdrawal  of  the  intravenous
infusion of SST did not led to immediate or delayed migraine-like headaches in migraineurs
or control subjects . 
Overall, further preclinical and clinical investigations are needed to clarify the putative role of
SST in the pathomechanism of migraine.
NOP
NOP (orphanin FQ), a 17-amino acid opioid-related peptide, is an endogenous ligand for the
orphan-like receptor 1, a member of the opioid receptor family (nowadays termed the NOP1
receptor) . The NOP1 receptor is widely distributed in the CNS, e.g. in the hypothalamus, the
brainstem and the dorsal horn of the spinal cord . NOP has multidirectional effects in the
CNS, exerting algesic, hyperalgesic and analgesic properties, while in the PNS it  displays
antinociceptive  effects  .  In  tracing  experiments  with  immunohistochemical  visualization,
NOP-ir fibres of trigeminal origin were detected in the dorsal horn of the cervical spinal cord .
In  the  human  TRIG,  78%  of  medium-sized  neurones  (30-60  um)  express  NOP
immunoreactivity . About 61% of the NOP-ir neurones are co-localized with CGRP, and 68%
of them contain PACAP . Interestingly, the human intracranial arteries (basilar and MCAs) do
not  demonstrate  NOP1 receptor  mRNA expression,  and  similarly  the  human  extracranial
temporal  artery  does  not  possess  NOP  immunoreactivity  .  NOP  does  not  influence  the
contractile properties of the human cerebral arteries . The migraine-related CNS structures,
such  as  the  TNC,  LC,  PAG,  raphe  nuclei,  thalamus  and  sensory  cortex,  display  NOP1
receptor expression . The meningeal vasculature is densely innervated by trigeminal sensory
nerve fibres (unmyelinated C-fibres and thinly myelinated Aδ fibres), and their activation can
result in neurogenic inflammation as a source of migraine pain . After electrical stimulation of
the MMA, neurogenic dural  vasodilatation  was observed in  an animal  model  of  a  closed
cranial  window  .  In  this  experimental  set-up,  intravenously  administered  NOP  dose-
dependently suppressed the neurogenic dural vasodilatation via NOP1 receptor activation . A
clinical study of the circulating NOP revealed a lower plasma NOP level in migraine patients
without aura during the headache-free period than in controls, and the level correlating with
the attack frequency . 
Thus,  the action of NOP on the NOP1 receptor  may play a role  in  the regulation  of the
vasomotor response of the cerebral dura mater and may be involved in the modulation of the
release of the neuropeptide from the trigeminal sensory nerve terminals. 
OXs
The OXs (also called hypocretins), derived from prepro-OX (130 amino acids), are orexin A
(OXA) (33 amino acids) and orexin B (OXB) (28 amino acids) . OXA is selectively bound to
the OX1 receptor (OX1R), while both OXA and OXB are bound to the OX2R . OXA and
OXB are exclusively synthesized in the lateral,  posterior and paraventricular nuclei  of the
hypothalamus . OX-containing neurones project to the different nociceptive areas of the brain,
e.g.  the  cerebral  cortex,  cingulate  cortex,  paraventricular  thalamic  nuclei  and  "migraine
generators", e.g. the LC, PAG and NRM . OX1R is selectively expressed in the LC, while
OX2R is expressed in the NRM . A functional imaging (H215O positron emission tomography)
study demonstrated hypothalamic activation (increased regional cerebral blood flow) during
spontaneous migraine attacks without aura . 
The OXs have the ability to modulate the TS . The OX-ergic system can attenuate neurogenic
dural vasodilatation via OX1R activation, which means inhibition of the TS . On the other
hand, the OXs can facilitate the TS via the OX2R . As concerns the OX-containing neurones
in the migraine-related structures, this activation is highest during wakefulness and inhibited
during sleep . The function of the OXs in sleep is the promotion of waking . Clinical studies
have revealed a high level of OXA in the CSF in chronic migraine patients, and mainly in
those with medication overuse headache . 
The simultaneous antagonism of the OX1R and the OX2R with dual OX receptor antagonist-
12  (DORA-12)  inhibited  trigeminal  sensory  neuronal  activation  in  the  TRIG  after  the
injection of complete Freund’s adjuvant to the temporomandibular joint in the rat . A recent
experimental  study in rats  yielded  evidence  that  DORA-12 resulted  in  attenuation  of  the
trigeminal nociceptive activity in the TNC after electrical stimulation of the dural trigeminal
afferents . However, a randomized double-blind placebo-controlled pilot trial revealed that an
OX receptor antagonist (filorexant, 10 mg nightly) failed to provide effectiveness as migraine
prophylaxis .
Overall,  it  emerges  that  the  OX1R and the OX2R may play a  role  in  modulation  of  the
nociceptive transmission in the TS, and the OX-ergic hypothalamic activation may be linked
to the pathomechanism of migraine. 
Neuropeptide-related migraine therapy 
SP
The role of NK1 as a receptor of SP has been investigated in preclinical and clinical studies
(Table 2). 
Under  experimental  conditions,  the  NK1  receptor  antagonists  proved  highly  potent  in
blocking plasma protein extravasation and diminishing the firing of second-order neurones in
the TNC . However, human clinical studies failed to confirm the efficacy of  NK1 receptor
antagonists . 
Orally administered lanepitant (LY-303,870), an NK1 receptor antagonist has been evaluated
for  both  the  acute  and  the  preventive  treatment  of  migraine.  A  double-blind  placebo-
controlled cross-over trial demonstrated that lanepitant was not superior to placebo in acute
migraine therapy . In a 12-week double-blind study, lanepitant was not effective in preventing
attacks of migraine with or without aura . 
Another orally administered NK1 receptor antagonist,  RPR100893, evaluated in a double-
blind,  randomized,  placebo-controlled  study,  proved  ineffective  in  the  treatment  of  acute
migraine . 
Likewise,  single dose of the intravenously administered  vofopitant  (GR-205,171)  was not
effective relative to placebo in the treatment of a single attack of migraine with or without
aura  .  Intravenous  infusion  of  fosaprepitant  (L-758,298),  a  prodrug of  the  NK1 receptor
antagonist L-754,030, did not abort the migraine pain during the headache attack in a double
blind study .
To summarize, NK1 receptor antagonists administered either orally or intravenously failed to
demonstrate superiority to placebo in either acute or preventive migraine therapy. 
CGRP
For  the  purpose  of  the  therapy  of  migraine  form  the  aspect  of  CGRP,  pharmaceutical
innovations have been introduced that target the CGRP receptors; these primarily involve the
development  of  antagonists  for  the  acute  treatment  of  migraine  and the  creation  of  fully
humanized  monoclonal  antibodies  against  CGRP  itself  and  the  CGRP  receptors  for  the
preventive treatment of migraine . 
CGRP receptor antagonists 
Small-molecule  CGRP receptor  antagonists  have been developed for  clinical  use in  acute
migraine treatment, e.g. olcegepant (BIBN4096BS), telcagepant (MK-0974), MK-3207, MK-
1602, BMS-694153, BMS-927711 and BI44370TA . Telcagepant has also been evaluated for
the prevention of migraine . 
Olcegepant  and telcagepant have been investigated intensively.  Intravenously administered
olcegepant  was  effective  relative  to  placebo  for  the  acute  treatment  of  migraine  in  a
multicentre  double-blind randomized study , and telcagepant  administered orally for acute
migraine therapy was similarly more effective than placebo . A randomized, double-blind,
placebo-controlled multicentre trial revealed that telcagepant reduced the number of migraine
headache days  as compared with placebo in a migraine prophylaxis  therapy .  Despite the
favourable  effects  of  the gepants  in  acute  and preventive  migraine  therapy,  in  their  liver
toxicity (elevation of the liver transaminases) limits their widespread clinical use . 
CGRP-targeting monoclonal antibodies
Three monoclonal antibodies (LY2951742, ALD403, and LBR-101) developed that target the
CGRP  have  so  far  been  for  the  prophylactic  treatment  of  migraine.  Besides  their
effectiveness, the favourable dosing (once or twice per month) promotes the adherence of
migraine patients to the treatment . An unfavourable feature is the route of administration,
which is subcutaneously or intravenously instead of orally . 
Only one monoclonal antibody that targets the CGRP receptor is currently available: AMG
334  .  The  subcutaneous  administration  of  AMG  334  once  per  month  is  undergoing
investigation for prevention of the episodic or chronic state of migraine, but clinical data have
not yet been published . The data reported to date indicate that fully humanized monoclonal
antibodies are promising therapeutic options for migraine prevention. 
In  summary,  neuropeptides  may well  have  a  role  in  the  acute  and preventive  therapy of
migraine headache. 
Conclusions
Although  migraine  dramatically  influences  the  quality  of  life  of  the  patients,  the  precise
pathomechanism of this type of primary headache disorder is still lacking. The neuropeptides
discussed  here  may  have  a  fundamental  role  in  the  processes  of  meningeal  neurogenic
inflammation and pain transmission in the TNC, and peripheral and central sensitization of
the TS. Animal experimenters in the field of migraine research still face the problem that on
appropriate animal migraine model does not yet exist.  Moreover, from a clinical aspect in
spite of the alterations in these neuropeptides in the different types of migraine (e.g. migraine
with or without aura, or episodic or chronic migraine), they have not achieved a function as
biomarkers. Notably, however, the actual level of any neuropeptide is determined by the rate
of biosynthesis and the rate of degradation. Therefore, the measured levels reflect a steady
state, from which far-reaching consequences cannot be drawn without the investigation of the
turnover. Further preclinical and clinical research is needed for a better understanding of the
roles of the neuropeptides in the pathomechanism of migraine headache. These neuropeptides
and their receptors could well be valuable targets for the acute and prophylactic treatment of
migraine in the near future.
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Figure legends
Figure 1. Putative mechanism of the activation of trigeminovascular system (modified 
from refs. 
Hypothethically,  cortical  spreading  depression  may  activate  the  meningeal  nociceptors  of
trigeminal sensory afferents,  resulting in a consequent release of vasoactive neuropeptides
(CGRP, SP, PACAP, VIP). These peptides evoke vasodilatation in the meningeal vasculature,
plasma  protein  extravasation  and  mast  cell  degranulation,  eventually  leading  to  the
sensitization  of  the  peripheral  nerve  branch  of  the  TRIG  (peripheral  sensitization).  This
process subsequently leads to the activation and sensitization of the second-order neurones in
the TNC and the third-order neurones of the thalamus (central sensitization). 
Abbreviations: CSD: cortical  spreading depression, CGRP: calcitonin gene-related peptide,
PACAP: pituitary adenylate cyclase-activating polypeptide, SP: substance P, TNC: trigeminal
nucleus caudalis, TRIG: trigeminal ganglion, VIP: vasoactive intestinal peptide
Figure 2. Alterations in the plasma PACAP-38 concentrations in healthy subjects and
migraineurs 
The concentration of PACAP-38 may be decreased in the plasma in the interictal period of
migraineurs as compared with healthy subjects. It is assumed that brain energy deficit (lactate,
magnesium,  etc.),  mitochondrial  disturbances,  impairment  of  blood-brain  barrier  (matrix
metalloproteases,  etc.)  and  neuronal/glial  damages  may  also  potentiate  the  decrease  in
PACAP-38 levels. Unknown trigger(s) can evoke elevated plasma PACAP-38 level during
the  attack  phase,  which  can  led  to  vasodilation,  mast  cell  degranulation,  neurogenic
inflammation, trigeminal activation, contributing the development of sensitization and serious
migraine headache. 
Figure  3.  PACAP-38-induced alterations in the trigeminovascular system in the ictal
period of migraineurs 
 It is assumed that PACAP-38 can be released from peripheral and central terminals of the
primary  sensory  neurons  in  the  attack  phase  of  migraineurs.  PACAP-38  has  direct  and
indirect sensitizing effects (vasodilation, mast cell degranulation, trigeminovascular activation
and sensitization) on meningeal vessels and in the area of second-order trigeminal sensory
neurons  in  the  brainstem.  The  peptide  may  enter  the  circulatory  system and an  elevated
PACAP-38 level can contribute to the development of migraine headache.
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